Cancer Vaccine CMC Strategy: FDA Expectations for Manufacturing and Regulatory Readiness
Cancer vaccine manufacturing companies engaging the FDA must demonstrate a clear, phase-appropriate CMC strategy that supports both clinical development and eventual licensure. FDA expectations for cancer vaccines, particularly personalized and combination products, extend beyond early IND readiness into manufacturing controls,...
